Androgen insensitivity syndrome: a review.


Journal

Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 01 02 2023
accepted: 31 05 2023
medline: 23 10 2023
pubmed: 10 6 2023
entrez: 10 6 2023
Statut: ppublish

Résumé

Androgen insensitivity syndrome (AIS) is a disorder characterized by peripheral androgen resistance due to androgen receptor mutations in subjects with 46 XY karyotype. The severity of hormone resistance (complete, partial or mild) determines the wide spectrum of phenotypes. We performed a literature review on Pubmed focusing on etiopathogenesis, molecular alterations, and diagnostic-therapeutic management. AIS is determined by a large variety of X-linked mutations that account for the wide phenotypic spectrum of subjects; it represents one of the most frequent disorders of sexual development (DSD). Clinical suspicion can arise at birth in partial AIS, due to the presence of variable degrees of ambiguity of the external genitalia, and at pubertal age in complete AIS, due to the development of female secondary sex characteristics, primary amenorrhea, and absence of female primary sex characteristics (uterus and ovaries). Laboratory tests showing elevated LH and testosterone levels despite mild or absent virilization may be helpful, but diagnosis can be achieved only after genetic testing (karyotype examination and androgen receptor sequencing). The clinical phenotype and especially the decision on sex assignment of the patient, if the diagnosis is made at birth or in the neonatal period, will guide the following medical, surgical and psychological management. For the management of AIS, a multidisciplinary team consisting of physicians, surgeons, and psychologists is highly recommended to support the patient and his/her family on gender identity choices and subsequent appropriate therapeutic decisions.

Identifiants

pubmed: 37300628
doi: 10.1007/s40618-023-02127-y
pii: 10.1007/s40618-023-02127-y
doi:

Substances chimiques

Receptors, Androgen 0
Androgens 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2237-2245

Subventions

Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca
ID : 2017S9KTNE_003

Informations de copyright

© 2023. The Author(s), under exclusive licence to Italian Society of Endocrinology (SIE).

Références

Hughes IA, Houk C, Ahmed SF, Lee PA, LWPES Consensus Group, ESPE Consensus Group (2006) Consensus statement on management of intersex disorders. Arch Dis Child 91(7):554–563. https://doi.org/10.1136/adc.2006.098319
doi: 10.1136/adc.2006.098319 pubmed: 16624884 pmcid: 2082839
Hughes IA, Davies JD, Bunch TI, Pasterski V, Mastroyannopoulou K, MacDougall J (2012) Androgen insensitivity syndrome. Lancet 380(9851):1419–1428. https://doi.org/10.1016/S0140-6736(12)60071-3
doi: 10.1016/S0140-6736(12)60071-3 pubmed: 22698698
Bertelloni S, Dati E, Baroncelli GI, Hiort O (2011) Hormonal management of complete androgen insensitivity syndrome from adolescence onward. Horm Res Paediatr 76(6):428–433. https://doi.org/10.1159/000334162
doi: 10.1159/000334162 pubmed: 22156544
Berglund A, Johannsen TH, Stochholm K, Viuff MH, Fedder J, Main KM, Gravholt CH (2016) Incidence, prevalence, diagnostic delay, and clinical presentation of female 46, XY disorders of sex development. J Clin Endocrinol Metab 101(12):4532–4540. https://doi.org/10.1210/jc.2016-2248
doi: 10.1210/jc.2016-2248 pubmed: 27603905
Boehmer AL, Brinkmann O, Brüggenwirth H, van Assendelft C, Otten BJ, Verleun-Mooijman MC, Niermeijer MF, Brunner HG, Rouwé CW, Waelkens JJ, Oostdijk W, Kleijer WJ, van der Kwast TH, de Vroede MA, Drop SL (2001) Genotype versus phenotype in families with androgen insensitivity syndrome. J Clin Endocrinol Metab 86(9):4151–4160. https://doi.org/10.1210/jcem.86.9.7825
doi: 10.1210/jcem.86.9.7825 pubmed: 11549642
Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM, French FS (1995) Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev 16(3):271–321. https://doi.org/10.1210/edrv-16-3-271
doi: 10.1210/edrv-16-3-271 pubmed: 7671849
Bhandari RK, Haque MM, Skinner MK (2012) Global genome analysis of the downstream binding targets of testis determining factor SRY and SOX9. PLoS ONE 7(9):e43380. https://doi.org/10.1371/journal.pone.0043380 . (Epub 2012 Sep 12)
doi: 10.1371/journal.pone.0043380 pubmed: 22984422 pmcid: 3440412
Sekido R, Lovell-Badge R (2008) Sex determination involves synergistic action of SRY and SF1 on a specific Sox9 enhancer. Nature 453(7197):930–934. https://doi.org/10.1038/nature06944 . (Epub 2008 May 4. Erratum in: Nature. 2008 Dec 11;456(7223):824)
doi: 10.1038/nature06944 pubmed: 18454134
Ostrer H, Huang HY, Masch RJ, Shapiro E (2007) A cellular study of human testis development. Sex Dev 1(5):286–292. https://doi.org/10.1159/000108930
doi: 10.1159/000108930 pubmed: 18391539
Pellegrino M, Maiorino R, Schonauer S (2010) WNT4 signaling in female gonadal development. Endocr Metab Immune Disord Drug Targets 10(2):168–174. https://doi.org/10.2174/187153010791213074
doi: 10.2174/187153010791213074 pubmed: 20350288
Nassar GN, Leslie SW (2023) Physiology, Testosterone. 2023 Jan 2. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing
Reyes FI, Boroditsky RS, Winter JS, Faiman C (1974) Studies on human sexual development. II. Fetal and maternal serum gonadotropin and sex steroid concentrations. J Clin Endocrinol Metab 38(4):612–617. https://doi.org/10.1210/jcem-38-4-612
doi: 10.1210/jcem-38-4-612 pubmed: 4856555
Nagamani M, McDonough PG, Ellegood JO, Mahesh VB (1979) Maternal and amniotic fluid steroids throughout human pregnancy. Am J Obstet Gynecol 134(6):674–680. https://doi.org/10.1016/0002-9378(79)90649-5
doi: 10.1016/0002-9378(79)90649-5 pubmed: 463959
Winter JS, Hughes IA, Reyes FI, Faiman C (1976) Pituitary-gonadal relations in infancy: 2. Patterns of serum gonadal steroid concentrations in man from birth to two years of age. J Clin Endocrinol Metab 42(4):679–686. https://doi.org/10.1210/jcem-42-4-679
doi: 10.1210/jcem-42-4-679 pubmed: 1262442
Kuiri-Hänninen T, Sankilampi U, Dunkel L (2014) Activation of the hypothalamic-pituitary-gonadal axis in infancy: minipuberty. Horm Res Paediatr 82(2):73–80. https://doi.org/10.1159/000362414
doi: 10.1159/000362414 pubmed: 25012863
Bakker J, Brock O (2010) Early oestrogens in shaping reproductive networks: evidence for a potential organisational role of estradiol in female brain development. J Neuroendocrinol 22(7):728–735. https://doi.org/10.1111/j.1365-2826.2010.02016.x
doi: 10.1111/j.1365-2826.2010.02016.x pubmed: 20456606
Arnold AP, Xu J, Grisham W, Chen X, Kim YH, Itoh Y (2004) Minireview: sex chromosomes and brain sexual differentiation. Endocrinology 145(3):1057–1062. https://doi.org/10.1210/en.2003-1491
doi: 10.1210/en.2003-1491 pubmed: 14670983
Masica DN, Money J, Ehrhardt AA (1971) Fetal feminization and female gender identity in the testicular feminizing syndrome of androgen insensitivity. Arch Sex Behav 1(2):131–142. https://doi.org/10.1007/BF01541057
doi: 10.1007/BF01541057 pubmed: 24179056
Hines M, Ahmed SF, Hughes IA (2003) Psychological outcomes and gender-related development in complete androgen insensitivity syndrome. Arch Sex Behav 32(2):93–101. https://doi.org/10.1023/a:1022492106974
doi: 10.1023/a:1022492106974 pubmed: 12710824
T’Sjoen G, De Cuypere G, Monstrey S, Hoebeke P, Freedman FK, Appari M, Holterhus PM, Van Borsel J, Cools M (2011) Male gender identity in complete androgen insensitivity syndrome. Arch Sex Behav 40(3):635–638. https://doi.org/10.1007/s10508-010-9624-1
doi: 10.1007/s10508-010-9624-1 pubmed: 20358272
Brunner F, Fliegner M, Krupp K, Rall K, Brucker S, Richter-Appelt H (2016) Gender role, gender identity and sexual orientation in CAIS (“XY-Women”) compared with subfertile and infertile 46,XX Women. J Sex Res 53(1):109–124. https://doi.org/10.1080/00224499.2014.1002124
doi: 10.1080/00224499.2014.1002124 pubmed: 26133743
Savic I, Frisen L, Manzouri A, Nordenstrom A, Lindén Hirschberg A (2017) Role of testosterone and Y chromosome genes for the masculinization of the human brain. Hum Brain Mapp 38(4):1801–1814. https://doi.org/10.1002/hbm.23483
doi: 10.1002/hbm.23483 pubmed: 28070912 pmcid: 6867124
Gottlieb B, Beitel LK, Nadarajah A, Paliouras M, Trifiro M (2012) The androgen receptor gene mutations database: 2012 update. Hum Mutat 33(5):887–894. https://doi.org/10.1002/humu.22046 . (Epub 2012 Mar 13)
doi: 10.1002/humu.22046 pubmed: 22334387
Zhou D, Xu H, Shen X, Gu R, Chen Y, Chen G, Li P, Shi H, Sun X, Xin A (2022) Complete androgen insensitivity syndrome caused by a novel mutation in the androgen receptor gene and its mechanism. Clin Chim Acta 531:94–99. https://doi.org/10.1016/j.cca.2022.03.021
doi: 10.1016/j.cca.2022.03.021 pubmed: 35351434
Chen G, Zhao D, Zhu L, Zhao Y, Zhang J, Wang X, Tian H, Tang D, Shu Q, Qiao S (2022) Novel androgen receptor gene variant containing a frameshift mutation in a patient with complete androgen insensitivity syndrome. Andrologia 54(2):e14292. https://doi.org/10.1111/and.14292
doi: 10.1111/and.14292 pubmed: 34700362
Zhang D, Yao F, Tian T, Deng S, Luo M, Tian Q (2021) Clinical characteristics and molecular genetics of complete androgen insensitivity syndrome patients: a series study of 30 cases from a Chinese tertiary medical center. Fertil Steril 115(5):1270–1279. https://doi.org/10.1016/j.fertnstert.2020.12.008
doi: 10.1016/j.fertnstert.2020.12.008 pubmed: 33602557
De Conti L, Baralle M, Buratti E (2013) Exon and intron definition in pre-mRNA splicing. Wiley Interdiscip Rev RNA 4(1):49–60. https://doi.org/10.1002/wrna.1140
doi: 10.1002/wrna.1140 pubmed: 23044818
Batista RL, Rodrigues AS, Nishi MY, Feitosa ACR, Gomes NLRA, Junior JAF, Domenice S, Costa EMF, de Mendonça BB (2017) Heterozygous nonsense mutation in the androgen receptor gene associated with partial androgen insensitivity syndrome in an individual with 47,XXY Karyotype. Sex Dev 11(2):78–81. https://doi.org/10.1159/000468957
doi: 10.1159/000468957 pubmed: 28456808
Hornig NC, Holterhus PM (2021) Molecular basis of androgen insensitivity syndromes. Mol Cell Endocrinol 523:111146. https://doi.org/10.1016/j.mce.2020.111146
doi: 10.1016/j.mce.2020.111146 pubmed: 33385475
Hughes IA, Werner R, Bunch T, Hiort O (2012) Androgen insensitivity syndrome. Semin Reprod Med 30(5):432–442. https://doi.org/10.1055/s-0032-1324728
doi: 10.1055/s-0032-1324728 pubmed: 23044881
Cools M, Drop SL, Wolffenbuttel KP, Oosterhuis JW, Looijenga LH (2006) Germ cell tumors in the intersex gonad: old paths, new directions, moving frontiers. Endocr Rev 27(5):468–484. https://doi.org/10.1210/er.2006-0005
doi: 10.1210/er.2006-0005 pubmed: 16735607
Bouvattier C, Carel JC, Lecointre C, David A, Sultan C, Bertrand AM, Morel Y, Chaussain JL (2002) Postnatal changes of T, LH, and FSH in 46, XY infants with mutations in the AR gene. J Clin Endocrinol Metab 87(1):29–32. https://doi.org/10.1210/jcem.87.1.7923
doi: 10.1210/jcem.87.1.7923 pubmed: 11788616
Hellmann P, Christiansen P, Johannsen TH, Main KM, Duno M, Juul A (2012) Male patients with partial androgen insensitivity syndrome: a longitudinal follow-up of growth, reproductive hormones and the development of gynaecomastia. Arch Dis Child 97(5):403–409. https://doi.org/10.1136/archdischild-2011-300584
doi: 10.1136/archdischild-2011-300584 pubmed: 22412043
Griffin JE, Edwards C, Madden JD, Harrod MJ, Wilson JD (1976) Congenital absence of the vagina. The Mayer-Rokitansky-Kuster-Hauser syndrome. Ann Intern Med 85(2):224–236. https://doi.org/10.7326/0003-4819-85-2-224
doi: 10.7326/0003-4819-85-2-224 pubmed: 782313
Singh S, Ilyayeva S (2022) Androgen Insensitivity Syndrome (2022) In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 31194363.
Savage MO, Chaussain JL, Evain D, Roger M, Canlorbe P, Job JC (1978) Endocrine studies in male pseudohermaphroditism in childhood and adolescence. Clin Endocrinol (Oxf) 8(3):219–231. https://doi.org/10.1111/j.1365-2265.1978.tb01498.x
doi: 10.1111/j.1365-2265.1978.tb01498.x pubmed: 147759
Han B, Zhu H, Yao H, Ren J, O’Day P, Wang H, Zhu W, Cheng T, Auchus RJ, Qiao J (2022) Differences of adrenal-derived androgens in 5α-reductase deficiency versus androgen insensitivity syndrome. Clin Transl Sci 15(3):658–666. https://doi.org/10.1111/cts.13184
doi: 10.1111/cts.13184 pubmed: 34755921
Dahiya S, Singh M, Mandal S, Jain SL, Rathore A, Lal P (2022) Androgen insensitivity syndrome: can cytology help? Cytopathology 33(2):249–252. https://doi.org/10.1111/cyt.13064
doi: 10.1111/cyt.13064 pubmed: 34599627
Hannema SE, Scott IS, Rajpert-De Meyts E, Skakkebaek NE, Coleman N, Hughes IA (2006) Testicular development in the complete androgen insensitivity syndrome. J Pathol 208(4):518–527. https://doi.org/10.1002/path.1890
doi: 10.1002/path.1890 pubmed: 16400621
Birnbaum W, Bertelloni S (2014) Sex hormone replacement in disorders of sex development. Endocr Dev 27:149–159. https://doi.org/10.1159/000363640
doi: 10.1159/000363640 pubmed: 25247652
Birnbaum W, Marshall L, Werner R, Kulle A, Holterhus PM, Rall K, Köhler B, Richter-Unruh A, Hartmann MF, Wudy SA, Auer MK, Lux A, Kropf S, Hiort O (2018) Oestrogen versus androgen in hormone-replacement therapy for complete androgen insensitivity syndrome: a multicentre, randomised, double-dummy, double-blind crossover trial. Lancet Diabetes Endocrinol 6(10):771–780. https://doi.org/10.1016/S2213-8587(18)30197-9
doi: 10.1016/S2213-8587(18)30197-9 pubmed: 30075954
Reddy DS (2004) Testosterone modulation of seizure susceptibility is mediated by neurosteroids 3alpha-androstanediol and 17beta-estradiol. Neuroscience 129(1):195–207. https://doi.org/10.1016/j.neuroscience.2004.08.002
doi: 10.1016/j.neuroscience.2004.08.002 pubmed: 15489042
Auer MK, Birnbaum W, Hartmann MF, Holterhus PM, Kulle A, Lux A, Marshall L, Rall K, Richter-Unruh A, Werner R, Wudy SA, Hiort O (2022) Metabolic effects of estradiol versus testosterone in complete androgen insensitivity syndrome. Endocrine 76(3):722–732. https://doi.org/10.1007/s12020-022-03017-8
doi: 10.1007/s12020-022-03017-8 pubmed: 35258786 pmcid: 9156500
Poujol N, Lobaccaro JM, Chiche L, Lumbroso S, Sultan C (1997) Functional and structural analysis of R607Q and R608K androgen receptor substitutions associated with male breast cancer. Mol Cell Endocrinol 130(1–2):43–51. https://doi.org/10.1016/s0303-7207(97)00072-5
doi: 10.1016/s0303-7207(97)00072-5 pubmed: 9220020
Amies Oelschlager AM, Debiec K (2019) Vaginal dilator therapy: a guide for providers for assessing readiness and supporting patients through the process successfully. J Pediatr Adolesc Gynecol 32(4):354–358. https://doi.org/10.1016/j.jpag.2019.05.002
doi: 10.1016/j.jpag.2019.05.002 pubmed: 31091469
Levin HS (2000) Tumors of the testis in intersex syndromes. Urol Clin North Am 27(3):543–551. https://doi.org/10.1016/s0094-0143(05)70101-4
doi: 10.1016/s0094-0143(05)70101-4 pubmed: 10985153
Rajpert-de Meyts E, Hoei-Hansen CE (2007) From gonocytes to testicular cancer: the role of impaired gonadal development. Ann N Y Acad Sci 1120:168–180. https://doi.org/10.1196/annals.1411.013
doi: 10.1196/annals.1411.013 pubmed: 18184914
Deans R, Creighton SM, Liao LM, Conway GS (2012) Timing of gonadectomy in adult women with complete androgen insensitivity syndrome (CAIS): patient preferences and clinical evidence. Clin Endocrinol (Oxf) 76(6):894–898. https://doi.org/10.1111/j.1365-2265.2012.04330.x
doi: 10.1111/j.1365-2265.2012.04330.x pubmed: 22211628
Barros BA, Oliveira LR, Surur CRC, Barros-Filho AA, Maciel-Guerra AT, Guerra-Junior G (2021) Complete androgen insensitivity syndrome and risk of gonadal malignancy: systematic review. Ann Pediatr Endocrinol Metab 26(1):19–23. https://doi.org/10.6065/apem.2040170.085
doi: 10.6065/apem.2040170.085 pubmed: 33819955 pmcid: 8026333
Cheikhelard A, Morel Y, Thibaud E, Lortat-Jacob S, Jaubert F, Polak M, Nihoul-Fekete C (2008) Long-term followup and comparison between genotype and phenotype in 29 cases of complete androgen insensitivity syndrome. J Urol 180(4):1496–1501. https://doi.org/10.1016/j.juro.2008.06.045
doi: 10.1016/j.juro.2008.06.045 pubmed: 18710728
Coutant R, de Casson FB, Rouleau S, Douay O, Mathieu E, Gatelais F, Bouhours-Nouet N, Voinot C, Audran M, Limal JM (2004) Divergent effect of endogenous and exogenous sex steroids on the insulin-like growth factor I response to growth hormone in short normal adolescents. J Clin Endocrinol Metab 89(12):6185–6192. https://doi.org/10.1210/jc.2004-0814
doi: 10.1210/jc.2004-0814 pubmed: 15579776
Perry RJ, Farquharson C, Ahmed SF (2008) The role of sex steroids in controlling pubertal growth. Clin Endocrinol (Oxf) 68(1):4–15. https://doi.org/10.1111/j.1365-2265.2007.02960.x
doi: 10.1111/j.1365-2265.2007.02960.x pubmed: 17645565
Ferlin A, Selice R, Carraro U, Foresta C (2013) Testicular function and bone metabolism–beyond testosterone. Nat Rev Endocrinol 9(9):548–554. https://doi.org/10.1038/nrendo.2013.135
doi: 10.1038/nrendo.2013.135 pubmed: 23856820
Döhnert U, Wünsch L, Hiort O (2017) Gonadectomy in complete androgen insensitivity syndrome: why and when? Sex Dev 11(4):171–174. https://doi.org/10.1159/000478082
doi: 10.1159/000478082 pubmed: 28719904
Tack LJW, Maris E, Looijenga LHJ, Hannema SE, Audi L, Köhler B, Holterhus PM, Riedl S, Wisniewski A, Flück CE, Davies JH, T’Sjoen G, Lucas-Herald AK, Evliyaoglu O, Krone N, Iotova V, Marginean O, Balsamo A, Verkauskas G, Weintrob N, Ellaithi M, Nordenström A, Verrijn Stuart A, Kluivers KB, Wolffenbuttel KP, Ahmed SF, Cools M (2018) Management of gonads in adults with androgen insensitivity: an international survey. Horm Res Paediatr 90(4):236–246. https://doi.org/10.1159/000493645
doi: 10.1159/000493645 pubmed: 30336477
Lucas-Herald A, Bertelloni S, Juul A, Bryce J, Jiang J, Rodie M, Sinnott R, Boroujerdi M, Lindhardt Johansen M, Hiort O, Holterhus PM, Cools M, Guaragna-Filho G, Guerra-Junior G, Weintrob N, Hannema S, Drop S, Guran T, Darendeliler F, Nordenstrom A, Hughes IA, Acerini C, Tadokoro-Cuccaro R, Ahmed SF (2016) The long-term outcome of boys with partial androgen insensitivity syndrome and a mutation in the androgen receptor gene. J Clin Endocrinol Metab 101(11):3959–3967. https://doi.org/10.1210/jc.2016-1372
doi: 10.1210/jc.2016-1372 pubmed: 27403927 pmcid: 5095251
Bouvattier C, Mignot B, Lefèvre H, Morel Y, Bougnères P (2006) Impaired sexual activity in male adults with partial androgen insensitivity. J Clin Endocrinol Metab 91(9):3310–3315. https://doi.org/10.1210/jc.2006-0218
doi: 10.1210/jc.2006-0218 pubmed: 16757528

Auteurs

E Delli Paoli (E)

Laboratory of Seminology‑Sperm Bank "Loredana Gandini", Department of Experimental Medicine, "Sapienza" University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.

S Di Chiano (S)

Laboratory of Seminology‑Sperm Bank "Loredana Gandini", Department of Experimental Medicine, "Sapienza" University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.

D Paoli (D)

Laboratory of Seminology‑Sperm Bank "Loredana Gandini", Department of Experimental Medicine, "Sapienza" University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.

A Lenzi (A)

Laboratory of Seminology‑Sperm Bank "Loredana Gandini", Department of Experimental Medicine, "Sapienza" University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.

F Lombardo (F)

Laboratory of Seminology‑Sperm Bank "Loredana Gandini", Department of Experimental Medicine, "Sapienza" University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.

F Pallotti (F)

Laboratory of Seminology‑Sperm Bank "Loredana Gandini", Department of Experimental Medicine, "Sapienza" University of Rome, Viale del Policlinico 155, 00161, Rome, Italy. francesco.pallotti@unikore.it.
Faculty of Medicine and Surgery, University of Enna "Kore", Contrada Santa Panasia, 94100, Enna, Italy. francesco.pallotti@unikore.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH